EHA 2020: Results of a study examining the safety and effectiveness of rituximab biosimilar Rixathon in combination with chemotheapy for treatment of first line treatment of diffuse large b-cell lymphoma.
EHA 2020: Results of a study examining the safety and effectiveness of rituximab biosimilar Rixathon in combination with chemotheapy for treatment of first line treatment of diffuse large b-cell lymphoma.